EGFR and non-small cell lung carcinoma: First-line treatment options of NSCLC patients harbouring EGFR-mutation include the EGFR tyrosine kinase inhibitors (TKIs), gefitinib, erlotinib, and afatinib all demonstrating improvements in progression-free survival (PFS) and quality of life, compared with platinum-based doublet chemotherapy.